This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Orth, S. R. Articles by Ritz, E. Search for Related Content PubMed PubMed Citation Articles by Orth, S. R. Articles by Ritz, E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

(Hypertension. 1998;31:995-1001.)
© 1998 American Heart Association, Inc.

Scientific Contributions

Nephroprotection of an ET_A-Receptor Blocker (LU 135252) in Salt-Loaded Uninephrectomized Stroke-Prone Spontaneously Hypertensive Rats

Stephan R. Orth; Jan P. Esslinger; Kerstin Amann; Ute Schwarz; Manfred Raschack; ; Eberhard Ritz

From the Departments of Internal Medicine and Pathology, Ruperto Carola University, Heidelberg, and Knoll AG, Ludwigshafen/Rhein, Germany.

Correspondence to Stephan R. Orth, MD, Medizinische Klinik, Bergheimer Str 56a, D-69115 Heidelberg, Germany.

Abstract—The present study was designed to assess whether the orally active and highly specific endothelin A (ET_A) receptor antagonist LU 135252 affects progressive renal dysfunction in a hypertensive rat model of renal damage, ie, the uninephrectomized (UNX) stroke-prone spontaneously hypertensive rat (SHRsp). The animals were examined on a normal salt (0.25%) diet and, to sensitize the kidney to hypertensive injury, also on a high salt (3%) diet. Stereological methods were used to quantify indices of glomerulosclerosis, vascular damage, and tubulointerstitial damage. Treatment with LU 135252 (100 mg/kg body wt) did not affect systolic blood pressure (BP) in animals on a normal salt diet during the whole period of the experiment (18 weeks) or in salt-loaded animals until week 10; subsequently, BP was slightly but significantly lower in salt-loaded UNX-SHRsp given LU 135252. Between weeks 6 and 12, 40% of the untreated UNX-SHRsp on a high salt diet, but none on a standard salt diet, died; such mortality was completely prevented by LU 135252. Indices of renal damage were more abnormal in salt-loaded UNX-SHRsp compared with UNX-SHRsp on a normal salt diet. Development of glomerulosclerosis and tubulointerstitial and vascular damage in UNX-SHRsp on high salt was completely prevented by LU 135252. The respective indices were no longer significantly different from those of salt-loaded sham-operated SHRsp controls. In the less severely damaged kidneys of UNX-SHRsp on normal salt, treatment with LU 135252 tended to ameliorate the indices, but the difference was not statistically significant. The results document a role of the ET system, specifically of ET_A receptors, in the development of progressive renal injury in salt-loaded UNX-SHRsp. LU 135252 completely prevented death and renal damage resulting from salt loading.

Key Words: endothelin • kidney • renal failure • receptors, endothelin • rats, inbred SHRsp

This article has been cited by other articles:

				B. J Epstein Efficacy and Safety of Darusentan: A Novel Endothelin Receptor Antagonist Ann. Pharmacother., July 1, 2008; 42(7): 1060 - 1069. [Abstract] [Full Text] [PDF]

				M. Wendel, L. Knels, W. Kummer, and T. Koch Distribution of Endothelin Receptor Subtypes ETA and ETB in the Rat Kidney J. Histochem. Cytochem., November 1, 2006; 54(11): 1193 - 1203. [Abstract] [Full Text] [PDF]

				I. Vaneckova, H. J. Kramer, A. Backer, Z. Vernerova, M. Opocensky, and L. Cervenka Early Endothelin-A Receptor Blockade Decreases Blood Pressure and Ameliorates End-Organ Damage in Homozygous Ren-2 Rats Hypertension, October 1, 2005; 46(4): 969 - 974. [Abstract] [Full Text] [PDF]

				R. Dikow, L. P. Kihm, M. Zeier, J. Kapitza, J. Tornig, K. Amann, C. Tiefenbacher, and E. Ritz Increased Infarct Size in Uremic Rats: Reduced Ischemia Tolerance? J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1530 - 1536. [Abstract] [Full Text] [PDF]

				K. Amann, A. Simonaviciene, T. Medwedewa, A. Koch, S. Orth, M.-L. Gross, C. Haas, A. Kuhlmann, W. Linz, B. Scholkens, et al. Blood Pressure-Independent Additive Effects of Pharmacologic Blockade of the Renin-Angiotensin and Endothelin Systems on Progression in a Low-Renin Model of Renal Damage J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2572 - 2584. [Abstract] [Full Text] [PDF]

				K. AMANN, G. MIL TENBERGER-MIL TENYI, A. SIMONOVICIENE, A. KOCH, S. ORTH, and E. RITZ Remodeling of Resistance Arteries in Renal Failure: Effect of Endothelin Receptor Blockade J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2040 - 2050. [Abstract] [Full Text] [PDF]

				Y. Matsumura, T. Kuro, Y. Kobayashi, F. Konishi, M. Takaoka, J. L. Wessale, T. J. Opgenorth, C. E. Gariepy, and M. Yanagisawa Exaggerated Vascular and Renal Pathology in Endothelin-B Receptor-Deficient Rats With Deoxycorticosterone Acetate-Salt Hypertension Circulation, November 28, 2000; 102(22): 2765 - 2773. [Abstract] [Full Text] [PDF]

				T. F. Luscher and M. Barton Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs Circulation, November 7, 2000; 102(19): 2434 - 2440. [Abstract] [Full Text] [PDF]

				S. Dhein, S. Hochreuther, C. a. d. Spring, K. Bollig, C. Hufnagel, and M. Raschack Long-Term Effects of the EndothelinA Receptor Antagonist LU 135252 and the Angiotensin-Converting Enzyme Inhibitor Trandolapril on Diabetic Angiopathy and Nephropathy in a Chronic Type I Diabetes Mellitus Rat Model J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 351 - 359. [Abstract] [Full Text]

				G. P. Rossi, A. Sacchetto, D. Rizzoni, S. Bova, E. Porteri, G. Mazzocchi, A. S. Belloni, M. Bahcelioglu, G. G. Nussdorfer, and A. C. Pessina Blockade of Angiotensin II Type 1 Receptor and Not of Endothelin Receptor Prevents Hypertension and Cardiovascular Disease in Transgenic (mREN2)27 Rats via Adrenocortical Steroid-Independent Mechanisms Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20(4): 949 - 956. [Abstract] [Full Text] [PDF]

				H. Berthold, A. Just, H. R. Kirchheim, and H. Ehmke Interaction Between Nitric Oxide and Endogenous Vasoconstrictors in Control of Renal Blood Flow Hypertension, December 1, 1999; 34(6): 1254 - 1258. [Abstract] [Full Text] [PDF]

				E. L. Schiffrin Role of Endothelin-1 in Hypertension Hypertension, October 1, 1999; 34(4): 876 - 881. [Abstract] [Full Text] [PDF]

				H. Ehmke, J. Faulhaber, K. Munter, M. Kirchengast, and R. J. Wiesner Chronic ETA Receptor Blockade Attenuates Cardiac Hypertrophy Independently of Blood Pressure Effects in Renovascular Hypertensive Rats Hypertension, April 1, 1999; 33(4): 954 - 960. [Abstract] [Full Text] [PDF]

				S. R. ORTH, G. ODONI, K. AMANN, P. STRZELCZYK, M. RASCHACK, and E. RITZ The ETA Receptor Blocker LU 135252 Prevents Chronic Transplant Nephropathy in the "Fisher to Lewis" Model J. Am. Soc. Nephrol., February 1, 1999; 10(2): 387 - 391. [Abstract] [Full Text]

				Y. Matsumura, N. Hashimoto, S. Taira, T. Kuro, R. Kitano, M. Ohkita, T. J. Opgenorth, and M. Takaoka Different Contributions of Endothelin-A and Endothelin-B Receptors in the Pathogenesis of Deoxycorticosterone Acetate–Salt–Induced Hypertension in Rats Hypertension, February 1, 1999; 33(2): 759 - 765. [Abstract] [Full Text] [PDF]

				E. L. A. Blezer, K. Nicolay, R. Goldschmeding, G. H. Jansen, H. A. Koomans, T. J. Rabelink, and J. A. Joles Early-Onset But Not Late-Onset Endothelin-A–Receptor Blockade Can Modulate Hypertension, Cerebral Edema, and Proteinuria in Stroke-Prone Hypertensive Rats Hypertension, January 1, 1999; 33(1): 137 - 144. [Abstract] [Full Text] [PDF]

				F. C. Luft, E. Mervaala, D. N. Muller, V. Gross, F. Schmidt, J. K. Park, C. Schmitz, A. Lippoldt, V. Breu, R. Dechend, et al. Hypertension-Induced End-Organ Damage : A New Transgenic Approach to an Old Problem Hypertension, January 1, 1999; 33(1): 212 - 218. [Abstract] [Full Text] [PDF]